1. Home
  2. JTAI vs ALZN Comparison

JTAI vs ALZN Comparison

Compare JTAI & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Jet.AI Inc.

JTAI

Jet.AI Inc.

HOLD

Current Price

$9.04

Market Cap

4.6M

Sector

Finance

ML Signal

HOLD

Logo Alzamend Neuro Inc.

ALZN

Alzamend Neuro Inc.

HOLD

Current Price

$1.15

Market Cap

3.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JTAI
ALZN
Founded
2018
2016
Country
United States
United States
Employees
8
N/A
Industry
Blank Checks
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.6M
3.9M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
JTAI
ALZN
Price
$9.04
$1.15
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$80.00
$28.00
AVG Volume (30 Days)
161.8K
46.7K
Earning Date
05-15-2026
03-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
22.99
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$0.73
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.04
$0.84
52 Week High
$10.41
$4.30

Technical Indicators

Market Signals
Indicator
JTAI
ALZN
Relative Strength Index (RSI) 66.84 53.10
Support Level $6.03 $1.03
Resistance Level $9.24 $1.25
Average True Range (ATR) 0.69 0.08
MACD 0.10 0.02
Stochastic Oscillator 88.29 55.17

Price Performance

Historical Comparison
JTAI
ALZN

About JTAI Jet.AI Inc.

Jet AI Inc is principally involved in the sale of jet cards, which enable holders to use certain aircraft owned, leased by, arranged, and/or managed by Jet Token and others at agreed-upon rates, as well as the sale of fractional interests in aircraft; and the operation of a proprietary booking platform, which functions as a prospecting and quoting platform to arrange private jet travel with third party carriers as well as through Jet Token's leased and managed aircraft.

About ALZN Alzamend Neuro Inc.

Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

Share on Social Networks: